Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04378010
Recruitment Status : Recruiting
First Posted : May 7, 2020
Last Update Posted : August 7, 2020
Sponsor:
Information provided by (Responsible Party):
Enanta Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

Condition or disease Intervention/treatment Phase
Non-Alcoholic Steatohepatitis Drug: EDP-305 1.5 mg Drug: EDP-305 2 mg Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 336 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)
Actual Study Start Date : January 27, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: EDP-305 1.5 mg
Once a day orally for 72 weeks
 Drug: EDP-305 1.5 mg
Tablet
Experimental: EDP-305 2 mg
Once a day orally for 72 weeks
 Drug: EDP-305 2 mg
Tablet
Placebo Comparator: Placebo
Once a day orally for 72 weeks
 Drug: Placebo
Tablet


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of subjects who achieve ≥1 stage improvement in fibrosis without worsening of steatohepatitis and/or resolution of steatohepatitis and no worsening of liver fibrosis as determined by liver biopsy [ Time Frame: Measurement at Week 72 ]

Secondary Outcome Measures :
  1. Safety as assessed by adverse events [ Time Frame: Up to 72 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent documentation signed and dated by the subject.
  • Male and female subjects, of all ethnic origins, between the ages of 18 and 75 years, inclusive.
  • Subjects of all ethnic origins should have a Body Mass Index (BMI) > 25 kg/m2 and ≥45 except for Asian subjects who qualify for the study with BMI > 23kg/m2.
  • Histological evidence of definite NASH based on NASH Clinical Research Network (CRN) criteria obtained from assessment of a liver biopsy by the central histopathologist. The biopsy may be obtained either 1) during the Screening window or 2) within 6 months prior to the Screening visit.
  • NAFLD Activity Score (NAS) of 4 or greater with a score of at least 1 in each component of the NAS (steatosis scored 0-3, lobular inflammation scored 0-3, ballooning scored 0-2).
  • Fibrosis stage 2 or 3 using the NASH CRN Histologic Scoring System.
  • Subjects must have Screening laboratory values for Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and HCV RNA, and Human Immunodeficiency Virus (HIV) 1 and 2 antibodies (Ab) as seronegative. [Note: subjects previously infected by chronic hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic response (SVR) for at least 3 years will be allowed.]
  • A woman of childbearing potential who is sexually active with a male must agree to use two effective methods of contraception from the date of Screening until 30 days after the last dose of study drug.
  • A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after the last dose of study drug.
  • Subject must be willing and able to adhere to the assessments, visit schedules, prohibitions and restrictions, as described in this protocol.

Exclusion Criteria:

  • Laboratory Screening results as indicated below:

    • Total white blood cells (WBC) <3000 cells/mm3
    • Absolute neutrophil count (ANC) <1500 cells/mm3
    • Platelet count <140,000/mm3
    • International Normalized Ratio, INR >1.2 (unless due to use of anticoagulants)
    • Estimated glomerular filtration rate (eGFR) < 60 mL/min according to the Modification of Diet in Renal Disease (MDRD) equation
    • AST ≥5× ULN
    • ALT ≥5× ULN
    • ALP ≥ 2x ULN
    • Total bilirubin > 1.5 times ULN during Screening. [Note: Patients with Gilbert's syndrome will be allowed following review by the Medical Monitor if they have a known history of Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count.]
  • Pregnant or nursing females.
  • MELD: Model for End-stage Liver Disease score >12.
  • Clinical or laboratory evidence of known chronic liver disease such as alcoholic liver disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).
  • History of acute liver complications due to gallstones (e.g., acute cholecystitis or acute biliary obstruction) unless the subject has had a cholecytectomy (more than 3 months prior to screening).
  • History of liver transplant, or current placement on a liver transplant list.
  • Hepatorenal syndrome (type I or II).
  • Prior variceal hemorrhage, uncontrolled encephalopathy, liver cirrhosis Child-Pugh Class A, B, and C, esophageal varices, or refractory ascites within the previous 6 months of Screening and/or histological presence of liver cirrhosis.
  • Prior or planned ileal resection, or prior or planned bariatric surgery. [Note: Subjects who have undergone gastric surgeries that do not affect drug absorption (e.g., gastric band or gastric sleeve procedures) will be allowed if they are stable for at least 1 year prior to Screening. Gastrectomy or Roux-en-Y bypass will be allowed if stable for at least 3 years prior to Screening.]
  • Subjects with clinically or otherwise documented cardiovascular or cerebrovascular disease including clinically significant anomalies of rhythm or pattern of ECG, that in the judgement of the Principal Investigator (PI) could affect the safety of the subject or their ability to comply with the study requirements.
  • HbA1c ≥ 9.5% within 60 days prior to Day 1.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04378010


Contacts
Layout table for location contacts
Contact: Enanta Pharmaceuticals, Inc 617 607 0705 nadda@enanta.com

Locations
Show Show 41 study locations
Sponsors and Collaborators
Enanta Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Enanta Pharmaceuticals, Inc Enanta Pharmaceuticals Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Enanta Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04378010    
Other Study ID Numbers: EDP 305-102
First Posted: May 7, 2020    Key Record Dates
Last Update Posted: August 7, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Enanta Pharmaceuticals:
Fatty Liver, non-alcoholic fatty liver disease, liver diseases, Digestive system diseases, NASH
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases